Advertisement
A live audio webcast of each presentation will be available under theinvestor relations section of Arena's website at http://www.arenapharm.com.Please connect to Arena's website several minutes prior to the start of theconference call to ensure adequate time for any software download that may benecessary.
Advertisement
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused ondiscovering, developing and commercializing oral drugs in four majortherapeutic areas: cardiovascular, central nervous system, inflammatory, andmetabolic diseases. Arena's most advanced product candidate, lorcaserin, isbeing investigated in a Phase 3 clinical trial program for the treatment ofobesity. Arena's broad pipeline of novel compounds targeting G protein-coupledreceptors, an important class of validated drug targets, includes compoundsbeing evaluated independently and with its partners, Merck & Co., Inc. andOrtho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals(R) and Arena(R) are registered service marks of thecompany. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Forward-Looking Statements
Certain statements in this press release are forward-looking statementsthat involve a number of risks and uncertainties. Such forward-lookingstatements include statements about Arena's strategy, preclinical and internaland partnered clinical programs, and ability to develop compounds andcommercialize drugs. For such statements, Arena claims the protection of thePrivate Securities Litigation Reform Act of 1995. Actual events or results maydiffer materially from Arena's expectations. Factors that could cause actualresults to differ materially from the forward-looking statements include, butare not limited to, Arena's planned clinical trials may not proceed at thetime Arena expects or at all, the results of preclinical studies or clinicaltrials may not be predictive of future results, Arena's ability to partnerlorcaserin, APD125, APD791 or other of its compounds or programs, the timing,success and cost of Arena's research, out-licensing endeavors and clinicaltrials, Arena's ability to obtain additional financing, Arena's ability toobtain and defend its patents, and the timing and receipt of payments andfees, if any, from Arena's collaborators. Additional factors that could causeactual results to differ materially from those stated or implied by Arena'sforward-looking statements are disclosed in Arena's filings with theSecurities and Exchange Commission. These forward-looking statements representArena's judgment as of the time of this release. Arena disclaims any intent orobligation to update these forward-looking statements, other than as may berequired under applicable law.-- ThinkEquity Partners' 5th Annual Growth Conference Presentation: Monday, September 17, 2007 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) at the St. Regis Hotel in San Francisco Presenting: Jack Lief, Arena's President and Chief Executive Officer -- Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference 2007 Presentation: Wednesday, September 19, 2007 at 11:20 a.m. British Summer Time (6:20 a.m. Eastern Time, 3:20 a.m. Pacific Time) at the Merrill Lynch Financial Centre in London Presenting: Jack Lief, Arena's President and Chief Executive Officer -- A.G. Edwards' Emerging Growth Conference 2007 Presentation: Wednesday, September 19, 2007 at 12:30 p.m. Eastern Time (9:30 a.m. Pacific Time) at the New York Palace Hotel in New York City Presenting: Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer --
